Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Novel AR antagonist ZR-291 exhibits potent preclinical activity in prostate cancer

Dec. 4, 2009

Small-molecule compound BRA-101 reduces DSS-induced murine colitis

Dec. 4, 2009

FIELD trial data support beneficial effects of fenofibrate in type 2 diabetes patients

Dec. 4, 2009

Prasugrel more effective than clopidogrel in CAD patients with type 2 diabetes

Dec. 4, 2009

New camptothecin conjugate evaluated in phase I trial in advanced solid tumors

Dec. 4, 2009

GSK-2126458 shows potent preclinical antitumor activity; phase I trial under way

Dec. 4, 2009

Data from phase I study on AS-703569 disclosed at 2009 AACR-NCI-EORTC meeting

Dec. 3, 2009

Interim data presented from AV-412 phase I trial in advanced solid tumors

Dec. 3, 2009

TRIN-2755 exhibits antitumor activity in multiple xenograft mouse models

Dec. 3, 2009

MK-1775 exhibits synergism with gemcitabine in pancreatic tumors in vivo

Dec. 3, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...